Vanda Pharmaceuticals Gains Ownership Of The U.S. NDA And IND Applications For PONVORY From A Johnson & Johnson Company, Which Now Fully Allows Vanda To Commercialize PONVORY In The U.S.
Portfolio Pulse from Benzinga Newsdesk
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has gained ownership of the U.S. New Drug Application and Investigational New Drug Applications for PONVORY® (ponesimod) from a Johnson & Johnson Company, allowing Vanda to fully commercialize the drug in the U.S.
May 30, 2024 | 9:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vanda Pharmaceuticals has acquired the U.S. NDA and IND applications for PONVORY® from a Johnson & Johnson Company, enabling it to fully commercialize the drug in the U.S.
The acquisition of the NDA and IND applications for PONVORY® allows Vanda to fully commercialize the drug in the U.S., which is likely to positively impact its stock price in the short term due to the potential for increased revenue.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100